Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical Limited has announced the successful completion of phase III clinical trials for its innovative drug Culmerciclib, which has shown promise in treating hormone receptor-positive, HER2-negative advanced breast cancer. The new drug application for Culmerciclib has been accepted by China’s National Medical Products Administration, marking a significant step towards offering a new treatment option for breast cancer patients. Culmerciclib’s enhanced inhibitory effects on CDK2 and CDK4 may improve resistance issues found with current treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.